Skip to main content
Resverlogix Corp. logo

Resverlogix Corp. — Investor Relations & Filings

Ticker · RVX ISIN · CA76128M1086 LEI · 529900VI46SAPCOSH758 TSX Real estate activities
Open in API
Filings indexed 195 across all filing types
Latest filing 2021-05-14 Regulatory Filings
Country CA Canada
Listing TSX RVX

About Resverlogix Corp.

https://www.resverlogix.com/

Resverlogix Corp. is a late-stage clinical biotechnology company specializing in the development of epigenetic therapies for chronic illnesses. The company's core scientific focus involves regulating the expression of disease-causing genes. Its lead drug candidate is Apabetalone, a small molecule inhibitor currently being advanced through clinical programs, including the BETonMACE trial. Apabetalone is primarily targeted toward treating cardiovascular diseases and complications associated with diabetes mellitus. Resverlogix aims to provide novel science and value-based health solutions to key stakeholders, including pharmaceutical companies, physicians, and health payer groups.

Recent filings

Filing Released Lang Actions
Report of exempt distribution excluding schedule 1 of Form 5.pdf
Regulatory Filings Classification · 100% confidence The document text is extremely short (150 characters) and does not contain any substantive content or financial data. It only contains a message about the PDF viewer being outdated and no actual report or announcement content is present. Therefore, it cannot be classified as any specific report type. Given the lack of content, the best fit is Regulatory Filings (RNS) as a fallback category for miscellaneous filings without substantive information.
2021-05-14 English
Report of exempt distribution excluding schedule 1 of Form 5.pdf
Regulatory Filings Classification · 100% confidence The document text is extremely short (150 characters) and does not contain any substantive content, financial data, or report details. It only contains a message about the PDF viewer being outdated and unable to display the content. There is no indication that this is a report itself or an announcement of a report. Given the lack of content and the nature of the message, the document does not fit any specific report category and defaults to Regulatory Filings (RNS) as a fallback category.
2021-05-05 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a US$6 million debenture financing transaction by Resverlogix Corp. It details the terms of the financing, including the issuance of secured convertible debentures and warrants, the interest rate, maturity, conversion price, and the use of proceeds. It also discusses the related party nature of the transaction and provides background on the company and its product. There are no financial statements, comprehensive financial data, or detailed analysis typical of financial reports such as Annual Reports (10-K) or Interim Reports (IR). The document is not a regulatory filing or certification, nor is it a report publication announcement. It is clearly an update on a capital raising activity, specifically a financing transaction. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (6689 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2021-05-05 English
News release - English.pdf
Regulatory Filings Classification · 90% confidence The document is a press release announcing the publication of a scientific article about the positive impact of the drug apabetalone on COVID-19 in human lung cells. It references the publication in a scientific journal and provides background on the drug and ongoing clinical studies. There are no financial statements, regulatory filings, or detailed financial data. The document is primarily an announcement of research findings and program updates, not a financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is also not a presentation, call transcript, or governance-related document. Given the nature of the content, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2021-04-20 English
Report of exempt distribution excluding schedule 1 of Form 5.pdf
Regulatory Filings Classification · 100% confidence The document text contains only a placeholder message indicating that the PDF viewer cannot display the document content. There is no substantive content related to any financial report, announcement, or filing. Therefore, it does not fit any specific filing category and should be classified as a Regulatory Filing (RNS) as a fallback category for miscellaneous or non-informative filings.
2021-04-16 English
Report of exempt distribution excluding schedule 1 of Form 5.pdf
Regulatory Filings Classification · 100% confidence The document text is extremely short (150 characters) and does not contain any substantive content or financial data. It only contains a message about the PDF viewer being outdated and unable to display the content. There is no report, announcement, or any other filing information present. Given the lack of content and the nature of the message, this is best classified as a Regulatory Filing (RNS) as a fallback category for miscellaneous filings that do not fit elsewhere.
2021-04-14 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.